Boehringer Ingelheim will lay off an unspecified number of Connecticut employees as the German pharmaceutical company makes changes in its workforce following a sales decline and other troubles.
The News-Times reports that the privately-held company would not say how many local workers will be affected. Spokeswoman Erin Crew said the reduction would affect fewer than 5 percent of the local workforce, or less than 90 workers of the local labor force of 1,800.
Boehringer Ingelheim reported a 5.4 percent decline in sales of prescription medications for the first half of 2014, citing continued challenges, including health care reform and a settlement over Pradaxa, its blood-thinning drug.
The company agreed in May to pay $650 million to settle state and federal lawsuits questioning the drug's safety and marketing.
